Science and Publications

BIAL Biotech is leveraging its expertise in lysosomal biology to develop novel small molecules to be used in the treatment of various neurodegenerative diseases. Our lead candidate, BIA 28-6156 / LTI-291, is being developed as a potential treatment for GBA-associated parkinsonism (GBA-AP). Existing therapies and treatments for Parkinson’s disease provide transient symptomatic benefits, but do not address the underlying disease process which drives disease progression.

BIAL Biotech is also investigating the composition of glycosphingolipids in blood from PD patients to determine whether such a “fingerprint” could serve as a predictive biomarker for identifying Parkinson’s disease patients that are likely to respond to BIA 28-6156 / LTI-291 or our other therapeutic drug candidates.

There is a high, unmet medical need for treatment of the fundamental causes of Parkinson’s disease and GBA-AP. Rather than merely providing symptomatic relief, therapies targeting the underlying biological causes of Parkinson’s disease could potentially slow disease progression in this condition.

Tabs

den Heijer J, Schmitz A, Lansbury P, Cullen V, Hilt D, Bonifati V & Jan Groeneveld G

Published: Nature Research Vol.:(0123456789) Scientific Reports volume 11, Article number: 161 (2021)

Di Martino S, Tardia P, Cilibrasi V, Lansbury P, Liu M, Skerlj R, etc.

Published: J. Med. Chem. 2020, 63, 3634−3664, Publication Date: March 16, 2020

Caputo S, Di Martino S, Cilibrasi V, Tardia P, Mazzonna M, Russo D, Lansbury P, Liu M, etc.

Published: J. Med. Chem. 2020, 63, 24, 15821–15851, Publication Date: December 8, 2020

den Heijer J, Cullen V, Quadri M, Schmitz A, Hilt D, Lansbury P, etc.

Published: Movement Disorders 02 July 2020 https://doi.org/10.1002/mds.28112

den Heijer J, Kruithof A, van Amerongen G, de Kam M, Thijssen E, Grievink H, Moerland M, Walker M, Been K, Skerlj R, Justman C, Dudgeon L, Lansbury P, Cullen V, Hilt D, Jan Groeneveld G

Published: 11 February 2021 https://doi.org/10.1111/bcp.14772